MAGEA10

MAGEA10 is a cancer-testis antigen encoding an intranuclear protein of approximately 70–72 kDa whose normal expression is restricted to spermatogonia and spermatocytes, with aberrant re-expression in diverse tumors (PMID:10446460, PMID:21710496). Its silencing in normal somatic tissue is enforced epigenetically: treatment of cancer cells with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine induces MAGEA10 expression (PMID:35117468). The protein contains an intrinsically disordered N-terminus whose first seven residues, harboring a PRAPKR linear motif, are required for protein expression level and nuclear localization, two properties that are genetically separable (PMID:38136576). Functionally, MAGEA10 promotes epithelial-mesenchymal transition: loss-of-function in oral squamous cell carcinoma cells activates E-cadherin while repressing N-cadherin and vimentin, with concomitant impairment of migration, invasion, and adhesion (PMID:28955754). As an immunotherapy target, MAGEA10 yields the HLA-A*02:01-restricted nonapeptide GLYDGMEHL recognized by cytotoxic T lymphocytes, and crystal structures of TCR/peptide-HLA complexes have defined the bound peptide conformation and the molecular basis of engineered TCR affinity and specificity (PMID:10352307, PMID:35851311). Beyond these roles, no enzymatic activity, direct binding partner, or detailed mechanism by which MAGEA10 regulates adhesion-molecule transcription has been characterized in the available corpus.

1. 1999 High

   Established the basic identity of the MAGEA10 product, defining it as a nuclear protein of defined size, a prerequisite for any functional study.

   Evidence In vitro translation, transfection, Western blot, and immunocytochemistry in melanoma cells

   PMID:10446460

   Open questions at the time

   • No functional activity assigned to the protein
   • No domain structure or interaction partners identified
2. 1999 High

   Answered whether MAGEA10 is an immunologically presented tumor antigen by identifying a specific HLA-A2.1-restricted epitope recognized by patient-derived CTLs, opening an immunotherapy rationale.

   Evidence CTL TNF-production and cytotoxicity assays against tumor lines expressing MAGEA10 and HLA-A2.1

   PMID:10352307

   Open questions at the time

   • Did not determine the protein's cellular function
   • Epitope processing details not resolved
3. 2004 Medium

   Showed MAGEA10 transcripts undergo alternative splicing in tumors, raising the question of isoform diversity in antigen expression.

   Evidence RT-PCR and DNA sequencing of primary esophageal adenocarcinoma samples

   PMID:15355897

   Open questions at the time

   • Functional consequence of splice variants unknown
   • Protein-level confirmation of variants not established
4. 2011 High

   Defined the normal tissue restriction of MAGEA10, confirming intranuclear localization and confining expression to male germ cells, the hallmark of a cancer-testis antigen.

   Evidence Validated monoclonal antibody and immunohistochemistry across a >2,500-specimen tissue microarray

   PMID:21710496

   Open questions at the time

   • No mechanism for nuclear retention identified
   • Function in spermatogenesis not addressed
5. 2017 Medium

   Provided the first functional role for MAGEA10, showing it drives epithelial-mesenchymal transition and tumor cell motility through regulation of cadherin and vimentin expression.

   Evidence Lentiviral shRNA knockdown in oral squamous cell carcinoma cells with migration, invasion, adhesion, 3D culture, and EMT-marker readouts

   PMID:28955754

   Open questions at the time

   • Mechanism linking MAGEA10 to adhesion-gene transcription not defined
   • Single lab and single cancer type
   • No direct molecular partners identified
6. 2020 Medium

   Established that MAGEA10's tumor-restricted expression is governed by DNA methylation, explaining its silencing in somatic tissue and offering a route to pharmacologically enhance antigen presentation.

   Evidence 5-aza-2'-deoxycytidine treatment of lung cancer lines with PCR/Western readouts and CTL cytotoxicity assay

   PMID:35117468

   Open questions at the time

   • Specific methylated regulatory elements not mapped
   • Single lab pharmacological inference
7. 2022 High

   Resolved the structural basis of MAGEA10 antigen recognition, defining the HLA-bound peptide conformation and how TCR engineering modulates affinity and cross-reactivity for therapeutic targeting.

   Evidence Four high-resolution X-ray crystal structures of TCR and TCR/pHLA complexes with site-directed mutagenesis

   PMID:35851311

   Open questions at the time

   • Addresses the presented peptide, not full-length protein function
   • In vivo efficacy of engineered TCRs not established here
8. 2023 High

   Mapped the determinants of MAGEA10 expression and nuclear localization to an intrinsically disordered N-terminal PRAPKR motif, showing these properties are genetically separable and N-terminus-dependent.

   Evidence Deletion and point mutagenesis with SDS-PAGE, expression, and fluorescence-microscopy localization readouts

   PMID:38136576

   Open questions at the time

   • Trans-acting factors recognizing the PRAPKR motif unidentified
   • Mechanism coupling the motif to protein stability unresolved
9. 2025 Low

   Extended MAGEA10's pro-tumor role to gastric cancer and linked it to histone deacetylase binding and cadherin regulation, hinting at a chromatin-associated mechanism.

   Evidence siRNA/shRNA knockdown in gastric cancer lines with proliferation/migration/invasion assays, GSEA, and cadherin analysis

   PMID:40890425

   Open questions at the time

   • HDAC association is computational (GSEA), not biochemically validated
   • Direct interaction with HDACs not demonstrated
   • Cadherin regulation inferred without mechanistic follow-up

• The biochemical activity of nuclear MAGEA10 and the direct molecular mechanism by which it represses E-cadherin and activates mesenchymal genes remain undefined.
• No enzymatic or binding activity assigned
• No validated direct protein partner
• Link between nuclear localization and transcriptional output unestablished